Modulation of HIV-1 transcription by cytokines and chemokines

被引:30
作者
Copeland, KFT [1 ]
机构
[1] Ottawa Hlth Res Inst, Program Mol Med, Ottawa, ON K1H 8L6, Canada
关键词
transcription; HIV-1; LTR; cytokine; chemokine; replication; host protein; inflammatory;
D O I
10.2174/138955705774933383
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Infection with HIV results in the modulation of circulating levels of many host factors. Several host proteins that are up-regulated in HIV infection have the potential to influence virus replication. More specifically, the transcription of HIV-1 can be modulated in vivo by host proteins, including cytokines and chemokines. Cytokines modulate transcription mediated by the HIV-1 long terminal repeat (LTR) via multiple signal transduction pathways with resulting recruitment of numerous transcription factors, including NF kappa B, C/EBP, AP-1, TCF-1 alpha, NF-IL-6 and ISGF-3. The effects on transcription may vary depending upon the cell type studied and upon the timing of the exposure of infected or transfected cells to cytokines. Furthermore, studies of cytokine mediated activation or inhibition of LTR mediated transcription may also be affected by the presence of the HIV-1 trans-activating protein, Tat, which has significant impact upon the redox state of the cell. This review will examine the complexities of the positive and negative control of HIV transcription by cytokines and chemokines.
引用
收藏
页码:1093 / 1101
页数:9
相关论文
共 189 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]   Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration [J].
Amendola, A ;
Poccia, F ;
Martini, F ;
Gioia, C ;
Galati, V ;
Pierdominici, M ;
Marziali, M ;
Pandolfi, F ;
Colizzi, V ;
Piacentini, M ;
Girardi, E ;
D'Offizi, G .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 120 (02) :324-332
[3]   A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects [J].
Angel, JB ;
Jacobson, MA ;
Skolnik, PR ;
Giordano, M ;
Shapiro, L ;
LeBeaut, A ;
Greaves, W ;
Fuchs, AC .
AIDS, 2000, 14 (16) :2503-2508
[4]   Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression [J].
Angel, JB ;
High, K ;
Rhame, F ;
Brand, D ;
Whitmore, JB ;
Agosti, JM ;
Gilbert, MJ ;
Deresinski, S .
AIDS, 2000, 14 (04) :387-395
[5]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[6]   CCR2-64I allele and genotype association with delayed AIDS progression in African women [J].
Anzala, AO ;
Ball, TB ;
Rostron, T ;
O'Brien, SJ ;
Plummer, FA ;
Rowland-Jones, SL .
LANCET, 1998, 351 (9116) :1632-1633
[7]   CYTOKINES - COORDINATORS OF IMMUNE AND INFLAMMATORY RESPONSES [J].
ARAI, K ;
LEE, F ;
MIYAJIMA, A ;
MIYATAKE, S ;
ARAI, N ;
YOKOTA, T .
ANNUAL REVIEW OF BIOCHEMISTRY, 1990, 59 :783-836
[8]   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load [J].
Arnó, A ;
Ruiz, L ;
Juan, M ;
Jou, A ;
Balagué, M ;
Zayat, MK ;
Marfil, S ;
Martínez-Picado, J ;
Martínez, MA ;
Romeu, J ;
Pujol-Borrell, R ;
Lane, C ;
Clotet, B .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (01) :56-60
[9]   BRONCHIAL EPITHELIAL-CELLS OF PATIENTS WITH ASTHMA RELEASE CHEMOATTRACTANT FACTORS FOR T-LYMPHOCYTES [J].
BELLINI, A ;
YOSHIMURA, H ;
VITTORI, E ;
MARINI, M ;
MATTOLI, S .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 92 (03) :412-424
[10]  
BENNETT S, 1994, J LEUKOCYTE BIOL, V56, P236